Fig. 1

Palbociclib attenuation of mast cell degranulation. a Cell viability of B LCs following DNP-HSA challenge with or without 1-h palbociclib pretreatment (BLCs had been anti-DNP IgE-sensitized and incubated with palbociclib for 24 h prior to the challenge). b β-Hexosaminidase release from BLCs in a. c Histamine release from BLCs in A. d Flow cytometric analysis of CD63 expression in BLCs. e β-Hexosaminidase release from BMMCs stimulated with 100 ng/ml DNP-HSA for 30 min (prior 50 ng/ml DNP-specific IgE priming with or without 1-h palbociclib pretreatment). Means ± SDs of 3 independent experiments are shown; *p < 0.05, **p < 0.01 vs. the HSA-DNP group